Durability of the improvement of collagen I and collagen III with the use of oral isotretinoin in the treatment of photoaging.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
12
09
2023
received:
11
06
2023
accepted:
20
09
2023
medline:
15
11
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
ppublish
Résumé
Oral isotretinoin (ISO) is the drug of choice for the treatment of severe acne. For photoaging treatment, ISO has been proved to be effective in some controlled and noncontrolled trials and is an alternative to topical retinoic acid (RA) therapy, which causes an expected skin irritation. To evaluate and compare the skin remodeling in patients taking ISO 20 mg 3 times a week for 12 weeks and 12 weeks after the end of the treatment to quantify collagen I and collagen III augmentation. Immunohistochemical studies were performed to evaluate the expression of collagen I and collagen III, metalloproteinases (MMPs) -1, -3, -7, -9, -12, and the tissue inhibitor of MMP type-1 (TIMP-1) of the skin of 20 45 to 50-year-old women through morphometry in a semiquantitative method. The inclusion criteria were facial aging 2 and 3 of Glogau's classification, with phototypes between II and V who had not entered menopause. Biopsies of the skin of the left preauricular region were performed at three different times: pre-treatment (T0), end of 12-week treatment (T1), and 12 weeks posttreatment (T2). Collagen fibers I and III increased with statistical significance in T1 (50.7%; P = 0.012) but not in T2 (49.7%), which in turn was higher than in T0 (47.2%) for collagen I and T1 (33.3%; P = 0.002) but not in T2 (32.7%), and also was higher than T0 (32.0%) for collagen III. MMP-9 presented a decreased activity with statistical significance in T1 (P = 0.047) and T2 (P = 0.058). MMP-1 showed a reduction in T2 only (P = 0.015). MMPs -3, -7, -12, and TIMP-1 did not present significant modification in their expressions during or after the treatment. Low-dose ISO is effective in remodeling the extracellular matrix (ECM). This study found that the increase of collagen occurs through the augmentation of both collagen I and collagen III fibers. With originality, it was possible to verify the durability of these fibers for at least 12 weeks. This may be related to the decrease in MMP-9 expression verified at the end of the treatment and 12 weeks posttreatment.
Sections du résumé
BACKGROUND
BACKGROUND
Oral isotretinoin (ISO) is the drug of choice for the treatment of severe acne. For photoaging treatment, ISO has been proved to be effective in some controlled and noncontrolled trials and is an alternative to topical retinoic acid (RA) therapy, which causes an expected skin irritation.
OBJECTIVE
OBJECTIVE
To evaluate and compare the skin remodeling in patients taking ISO 20 mg 3 times a week for 12 weeks and 12 weeks after the end of the treatment to quantify collagen I and collagen III augmentation.
MATERIAL AND METHODS
METHODS
Immunohistochemical studies were performed to evaluate the expression of collagen I and collagen III, metalloproteinases (MMPs) -1, -3, -7, -9, -12, and the tissue inhibitor of MMP type-1 (TIMP-1) of the skin of 20 45 to 50-year-old women through morphometry in a semiquantitative method. The inclusion criteria were facial aging 2 and 3 of Glogau's classification, with phototypes between II and V who had not entered menopause. Biopsies of the skin of the left preauricular region were performed at three different times: pre-treatment (T0), end of 12-week treatment (T1), and 12 weeks posttreatment (T2).
RESULTS
RESULTS
Collagen fibers I and III increased with statistical significance in T1 (50.7%; P = 0.012) but not in T2 (49.7%), which in turn was higher than in T0 (47.2%) for collagen I and T1 (33.3%; P = 0.002) but not in T2 (32.7%), and also was higher than T0 (32.0%) for collagen III. MMP-9 presented a decreased activity with statistical significance in T1 (P = 0.047) and T2 (P = 0.058). MMP-1 showed a reduction in T2 only (P = 0.015). MMPs -3, -7, -12, and TIMP-1 did not present significant modification in their expressions during or after the treatment.
CONCLUSIONS
CONCLUSIONS
Low-dose ISO is effective in remodeling the extracellular matrix (ECM). This study found that the increase of collagen occurs through the augmentation of both collagen I and collagen III fibers. With originality, it was possible to verify the durability of these fibers for at least 12 weeks. This may be related to the decrease in MMP-9 expression verified at the end of the treatment and 12 weeks posttreatment.
Substances chimiques
Isotretinoin
EH28UP18IF
Tissue Inhibitor of Metalloproteinase-1
0
Matrix Metalloproteinase 9
EC 3.4.24.35
Collagen
9007-34-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1538-1542Informations de copyright
© 2023 the International Society of Dermatology.
Références
Raduan AP, Luiz RR, Manela-Azulay M. Association between smoking and cutaneous ageing in a Brazilian population. J Eur Acad Dermatol Venereol. 2008;22:1312-1318.
Yaar M, Gilchrest BA. Photoageing: mechanism, prevention and therapy. Br J Dermatol. 2007;157:874-887.
Bagatin E, Guadanhim LRS, Enokihara MMSS, Sanudo A, Talarico S, Miot HA. Low-dose oral isotretinoin versus topical retinoic acid for photoaging:a randomized, comparative study. Int J Dermatol. 2014;53:114-122.
Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin for photoaged skin. J Am Acad Dermatol. 1986;15:836-859.
Kim M-S, Lee S, Rho HS, Kim DH, Chang IS, Chung JH. The effects of a novel synthetic retinoid, seletinoid G, on the expression of extracellular matrix proteins in aged human skin in vivo. Clin Chim Acta. 2005;362:161-169.
Riahi RR, Bush AE, Cohen PR. Topical retinoids: therapeutic mechanisms in the treatment of photodamaged skin. Am J Clin Dermatol. 2016;17:265-276.
Hernandez-Perez E, Khawaja HA, Alvarez TY. Oral isotretinoin as part of the treatment of cutaneous aging. Dermatol Surg. 2000;26:649-652.
Kalil CL, Fachinello FZ, Lamb FM, Comunello LN. Use of oral isotretinoin in photoaging therapy. Skinmed. 2008;7:10-14.
Rabello-Fonseca RMR, Azulay DR, Luiz RR, Mandarim de Lacerda CA, Cuzzi T, Manela-Azulay M. Oral isotretinoin in photoaging: clinical and histopathological evidence of efficacy of an off label indication. J Eur Acad Dermatol Venereol. 2009;23:115-123.
Bagatin E, Parada MO, Miot HA, Hassum KM, Michalany N, Talarico S. A randomized controlled trial about the use of oral isotretinoin for photoaging. Int J Dermatol. 2010;49:207-214.
Bravo BSF, Azulay DR, Luiz RR, Mandarim-de-Lacerda CA, Cuzzi T, Manela-Azulay M. Avaliação e acompanhamento dos efeitos clínico-histológicos da isotretinoína oral no fotoenvelhecimento. An Bras Dermatol. 2015;90:478-486.
Blanner WS. Cellular metabolism and actions of 13-cis retinoic acid. J Am Acad Dermatol. 2002;45:S129-S135.
Azulay DR. Estudo do colágeno através da imunohistoquímica com o uso da isotretinoína oral no tratamento do fotoenvelhecimento [Tese]. Rio de Janeiro: Universidade Federal do Rio de Janeiro; 2018.
Helps SC, Thornton E, Kleining TJ, Manavis J, Vink R. Automatic non subjective estimation of antigen content visualized by immunohistochemistry using colour deconvolution. Appl Immunohistochem Mol Morphol. 2012;20:82-90.
Bakos RM, Bakos L, Edelweiss MI, Cartell A, Mariante JC, Masiero NC. Immunohistochemical expression of matrix metalloproteinase-2 and -9 in melanocytic nevi is altered by ultraviolet B. Photodermatol Photoimmunol Photomed. 2007;23:250-254.
Manela-Azulay M, Mandarim-de-Lacerda CA, Perez MA, Filgueira AL, Cuzzi T. Vitamina C. An Bras Dermatol. 2003;78:265-272.
Fulton JE, Porumb S. Chemical peels: their place within the range of resurfacing techniques. Am J Clin Dermatol. 2004;5:179-187.
Roy D. Ablative facial resurfacing. Dermatol Clin. 2005;23:549-559.
Dierickx CC, Anderson RR. Visible light treatment of photoaging. Dermatol Ther. 2005;18:191-208.
Issa MCA, Piñeiro-Maceira J, Farias RE, Pureza M, Luiz RR, Manela-Azulay M. Immunohistochemical expression of matrix metalloproteinases in photodamaged skin by photodynamic therapy. Br J Dermatol. 2009;161:547-553.
Wanick FBF, Issa MCA, Luiz RR, Filho PJS, Olej B. Skin remodeling using hyaluronic acid filler injections in photo-aged faces. Dermatol Surg. 2016;42:352-359.
Lateef H, Stevens MJ, Varani J. All-trans-retinoic acid suppresses matrix metalloproteinase activity and increases collagen synthesis in diabetic human skin in organ culture. Am J Pathol. 2004;165(1):167-174. https://doi.org/10.1016/S0002-9440(10)63285-3
Papakonstantinou E, Aletras AJ, Glass E, Tsogas P, Dionyssopoulos A, Adjaye J, et al. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol. 2005;125:673-684.
Kimura K, Zhou H, Orita T, Kobayashi S, Wada T, Yoshikuni Nakamura Y, et al. Inhibition by all-trans retinoic acid of collagen degradation mediated by corneal fibroblasts. Clin Exp Ophthalmol. 2016;44:502-508. 10.1111/ceo.12709
Dutta A, Sen T, Chatterjee A. All-trans retinoic acid (ATRA) downregulates MMP-9 by modulating its regulatory molecules. Cell Adh Migr. 2010;4(3):409-418.
DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol. 2001;45(5):S176-S182.
DiGiovanna JJ. Retinoid chemoprevention in the high-risk patient. J Am Acad Dermatol. 1998;39(2 Pt 3):S82-S85.
Tangrea JA, Edwards BK, Taylor PR, Hartman AM, Peck GL, Salasche SJ, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst. 1992;84(5):328-332.
Honeybrook A, Bernstein E. Oral isotretinoin and photoaging: a review. J Cosmet Dermatol. 2020;19(7):1548-1554. https://doi.org/10.1111/jocd.13467
Correia G, Magina S. Efficacy of topical vitamin C in melasma and photoaging: a systematic review. J Cosmet Dermatol. 2023;22(7):1938-1945. https://doi.org/10.1111/jocd.15748